4 results
Approved WMOPending
To assess whether testing for fibronectin is a cost-effective strategy that prevents unnecessary treatment in women with threatened preterm labour.
Approved WMOPending
To evaluate the effectiveness of tocolytic maintenance therapy for postponing delivery after initial 48-hour tocolytic therapy in women with threatened preterm birth from 24-32 weeks gestational age.
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
To assess whether in women with early PPROM tocolytics improve perinatal outcome.